{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:58:36Z","timestamp":1791212316675,"version":"4.1.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.rdc.2012.08.017","type":"journal-article","created":{"date-parts":[[2012,9,23]],"date-time":"2012-09-23T18:00:46Z","timestamp":1348423246000},"page":"583-600","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Therapy for Spondyloarthritis"],"prefix":"10.1016","volume":"38","author":[{"given":"Philippe","family":"Carron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbet","family":"Van Praet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Jacques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Elewaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4 Suppl 55","key":"10.1016\/j.rdc.2012.08.017_bib1","first-page":"S56","article-title":"Extra-articular manifestations","volume":"27","author":"Mielants","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.017_bib2","first-page":"354","article-title":"The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice","volume":"66","author":"Vander Cruyssen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.017_bib3","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/rheumatology\/kep146","article-title":"Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice","volume":"48","author":"Elewaut","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.rdc.2012.08.017_bib4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0002-9394(14)74218-7","article-title":"Clinical features of acute anterior uveitis","volume":"103","author":"Rothova","year":"1987","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.rdc.2012.08.017_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF00163549","article-title":"The natural history of uveitis","volume":"14","author":"Nussenblatt","year":"1990","journal-title":"Int Ophthalmol"},{"issue":"4","key":"10.1016\/j.rdc.2012.08.017_bib6","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bjo.80.4.332","article-title":"Causes and frequency of blindness in patients with intraocular inflammatory disease","volume":"80","author":"Rothova","year":"1996","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.rdc.2012.08.017_bib7","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/S0161-6420(98)99033-9","article-title":"Outcomes in anterior uveitis associated with the HLA-B27 haplotype","volume":"105","author":"Power","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/j.rdc.2012.08.017_bib8","first-page":"1112","article-title":"Bowel inflammation in anterior uveitis and spondyloarthropathy","volume":"22","author":"Banares","year":"1995","journal-title":"J\u00a0Rheumatol"},{"issue":"18","key":"10.1016\/j.rdc.2012.08.017_bib9","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMra041320","article-title":"Psoriasis","volume":"352","author":"Schon","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.rdc.2012.08.017_bib10","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.2165\/00003495-200262170-00004","article-title":"Diagnosis and management of psoriatic arthritis","volume":"62","author":"Brockbank","year":"2002","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.rdc.2012.08.017_bib11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2165\/00128071-200304070-00001","article-title":"Prevalence of joint disease in patients with psoriasis: implications for therapy","volume":"4","author":"Zachariae","year":"2003","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.rdc.2012.08.017_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2004.06.013","article-title":"Diagnosis and treatment of psoriatic arthritis","volume":"52","author":"Mease","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.rdc.2012.08.017_bib13","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/00015550252948130","article-title":"Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study","volume":"82","author":"Zachariae","year":"2002","journal-title":"Acta Derm Venereol"},{"issue":"Suppl 2","key":"10.1016\/j.rdc.2012.08.017_bib14","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.017_bib15","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.017_bib16","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jaad.2008.10.055","article-title":"Increasing use of more potent treatments for psoriasis","volume":"60","author":"Strowd","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.rdc.2012.08.017_bib17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaad.2009.03.027","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents","volume":"61","author":"Menter","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.rdc.2012.08.017_bib18","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0190-9622(86)70265-X","article-title":"Drugs in exacerbation of psoriasis","volume":"15","author":"Abel","year":"1986","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.rdc.2012.08.017_bib19","first-page":"45","article-title":"Exacerbation of psoriasis by ibuprofen","volume":"38","author":"Ben-Chetrit","year":"1986","journal-title":"Cutis"},{"key":"10.1016\/j.rdc.2012.08.017_bib20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/archderm.1990.01670280071013","article-title":"Sulfasalazine improves psoriasis: a double-blind analysis","volume":"126","author":"Gupta","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.rdc.2012.08.017_bib21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/archderm.1958.01560080060010","article-title":"Treatment of psoriasis with folic acid antagonists","volume":"78","author":"Edmunson","year":"1958","journal-title":"AMA Arch Derm"},{"key":"10.1016\/j.rdc.2012.08.017_bib22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000252574","article-title":"Methotrexate for psoriasis in weekly oral doses without any adjunctive therapy","volume":"140","author":"Nyfors","year":"1970","journal-title":"Dermatologica"},{"key":"10.1016\/j.rdc.2012.08.017_bib23","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0733-8635(18)30050-0","article-title":"Methotrexate and other chemotherapeutic agents used to treat psoriasis","volume":"13","author":"Jeffes","year":"1995","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.rdc.2012.08.017_bib24","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1056\/NEJMoa021359","article-title":"Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis","volume":"349","author":"Heydendael","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2012.08.017_bib25","first-page":"116","article-title":"Methotrexate versus cyclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial","volume":"158","author":"Flytstrom","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.rdc.2012.08.017_bib26","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.rdc.2012.08.017_bib27","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/bmj.293.6549.731","article-title":"Clearance of psoriasis with low dose cyclosporine","volume":"293","author":"Griffiths","year":"1986","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.rdc.2012.08.017_bib28","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1001\/jama.1986.03380220076026","article-title":"Cyclosporine improves psoriasis in a double-blind study","volume":"256","author":"Ellis","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.rdc.2012.08.017_bib29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2133.1988.tb01772.x","article-title":"Low-dose cyclosporine A in severe psoriasis. A double-blind study","volume":"118","author":"Van Joost","year":"1988","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.rdc.2012.08.017_bib30","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1056\/NEJM199101313240501","article-title":"Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial","volume":"324","author":"Ellis","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2012.08.017_bib31","first-page":"527","article-title":"Treatment of psoriasis with intermittent short course cyclosporin (Neoral): a multicenter study","volume":"136","author":"Berth-Jones","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.rdc.2012.08.017_bib32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00128071-200102010-00007","article-title":"Cyclosporine in severe psoriasis: results of a meta-analysis in 579 patients","volume":"2","author":"Faerber","year":"2001","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.rdc.2012.08.017_bib33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1365-2133.1999.02977.x","article-title":"Intermittent short courses of cyclosporine (Neoral) for psoriasis unresponsive to topical therapy: a 1-year multicenter, randomized study; the PISCES Study Group","volume":"141","author":"Ho","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.rdc.2012.08.017_bib34","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1067\/mjd.2001.112400","article-title":"Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study","volume":"44","author":"Ho","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.rdc.2012.08.017_bib35","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"10.1016\/j.rdc.2012.08.017_bib36","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1468-3083.2011.03990.x","article-title":"Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists","volume":"25","author":"Paul","year":"2011","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.rdc.2012.08.017_bib37","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.139.6.719","article-title":"An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis","volume":"139","author":"Lebwohl","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.rdc.2012.08.017_bib38","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/art.21870","article-title":"Alefacept with methotrexate for the treatment of psoriatic arthritis: results from a double-blind, placebo-controlled study","volume":"54","author":"Mease","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.017_bib39","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2012.08.017_bib40","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.017_bib41","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.017_bib42","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"Suppl 3","key":"10.1016\/j.rdc.2012.08.017_bib43","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/annrheumdis-2012-eular.1961","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind, randomized, placebo-controlled study (RAPID-PSA)","volume":"71","author":"Mease","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.017_bib44","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2012.08.017_bib45","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.rdc.2012.08.017_bib46","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"31","key":"10.1016\/j.rdc.2012.08.017_bib47","first-page":"e1","article-title":"A\u00a0randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis","volume":"56","author":"Menter","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.rdc.2012.08.017_bib48","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.09.002","article-title":"A\u00a0randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis","volume":"56","author":"Moore","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.rdc.2012.08.017_bib49","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12 \u204423 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double- blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2012.08.017_bib50","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12 \u204423 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2012.08.017_bib51","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2012.08.017_bib52","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"issue":"Suppl 3","key":"10.1016\/j.rdc.2012.08.017_bib53","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/annrheumdis-2012-eular.1841","article-title":"Ustekinumab in patients with active psoriatic arthritis: results of the phase 3 multicenter, double-blind, placebo-controlled PSUMMIT I study","volume":"71","author":"McInnes","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.017_bib54","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A\u00a0randomized trial of ustekinumab, a human interleukin-12:23 monoclonal antibody, in patients with moderate-to-severe Crohn\u2019s disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.rdc.2012.08.017_bib55","first-page":"53","article-title":"Indomethacin in the treatment of uveitis: a double blind trial","volume":"85","author":"Perkins","year":"1965","journal-title":"Trans Ophthalmol Soc UK"},{"key":"10.1016\/j.rdc.2012.08.017_bib56","first-page":"103","article-title":"Ibuprofen in the treatment of uveitis","volume":"17","author":"March","year":"1985","journal-title":"Ann Ophthalmol"},{"key":"10.1016\/j.rdc.2012.08.017_bib57","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/bjo.57.12.892","article-title":"Treatment of anterior uveitis: comparison of oral oxyphenbutazone and topical steroids","volume":"57","author":"Hunter","year":"1973","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.rdc.2012.08.017_bib58","first-page":"1289","article-title":"Non-steroidal anti-inflammatory drug therapy in chronic childhood iridocyclitis","volume":"142","author":"Olson","year":"1988","journal-title":"Am J Dis Child"},{"issue":"2","key":"10.1016\/j.rdc.2012.08.017_bib59","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3109\/09273941003587558","article-title":"Nonsteroidal anti-inflammatory therapy and recurrent acute anterior uveitis","volume":"18","author":"Fiorelli","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.rdc.2012.08.017_bib60","first-page":"81","article-title":"Prevention of acute anterior uveitis associated with spondylarthropathy induced by salazosulfapyridine","volume":"60","author":"Dougados","year":"1993","journal-title":"Rev Rhum Ed Fr"},{"key":"10.1016\/j.rdc.2012.08.017_bib61","first-page":"1277","article-title":"Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period","volume":"30","author":"Munoz-Fernandez","year":"2003","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.017_bib62","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/eye.2000.84","article-title":"Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis","volume":"14","author":"Benitez-del-Castillo","year":"2000","journal-title":"Eye"},{"issue":"4","key":"10.1016\/j.rdc.2012.08.017_bib63","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.rdc.2012.08.017_bib64","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","article-title":"Methotrexate for ocular inflammatory diseases","volume":"116","author":"Gangaputra","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.rdc.2012.08.017_bib65","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12348-011-0047-5","article-title":"Corticosteroid-sparing therapy: practice patterns among uveitis specialists","volume":"2","author":"Esterberg","year":"2012","journal-title":"J\u00a0Ophthalmic Inflamm Infect"},{"issue":"8","key":"10.1016\/j.rdc.2012.08.017_bib66","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00417-011-1731-8","article-title":"Long-term results of therapy with mycophenolate mofetil in chronic non-infectious uveitis","volume":"249","author":"Doycheva","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.rdc.2012.08.017_bib67","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.017_bib68","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.017_bib69","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.017_bib70","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis; results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.017_bib71","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/art.22669","article-title":"Differences in the incidence of flares or new onset of inflammatory bowel disease in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents","volume":"57","author":"Braun","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.017_bib72","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.017_bib73","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/ard.2008.103192","article-title":"Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials","volume":"69","author":"Sieper","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.017_bib74","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/bjo.87.7.925","article-title":"Does etanercept induce uveitis?","volume":"87","author":"Reddy","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.rdc.2012.08.017_bib75","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/09273940600659393","article-title":"Etanercept (Enbrel)-associated inflammatory eye disease: case report and review of the literature","volume":"14","author":"Taban","year":"2006","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.rdc.2012.08.017_bib76","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1136\/ard.2006.052092","article-title":"Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study","volume":"65","author":"Guignard","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.rdc.2012.08.017_bib77","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.ophtha.2006.04.038","article-title":"Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation","volume":"113","author":"Galor","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.rdc.2012.08.017_bib78","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/ard.2007.077370","article-title":"Uveitis and tumour necrosis factor blockade in ankylosing spondylitis","volume":"67","author":"Coates","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2012.08.017_bib79","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3899\/jrheum.110865","article-title":"Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease","volume":"39","author":"Gaujoux-Viala","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.017_bib80","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","article-title":"Do tumor necrosis factor inhibitors cause uveitis? A registry-based study","volume":"56","author":"Lim","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.017_bib81","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1517\/13543784.2012.669372","article-title":"Current investigational drugs in psoriasis","volume":"21","author":"Ryan","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.rdc.2012.08.017_bib82","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000336338","article-title":"New treatment options for noninfectious uveitis","volume":"51","author":"Gomes Bittencourt","year":"2012","journal-title":"Dev Ophthalmol"},{"key":"10.1016\/j.rdc.2012.08.017_bib83","unstructured":"Certolizumab pegol in subjects with active axial spondyloarthritis. Available at: ClinicalTrials.gov [Identifier: NCT01087762]. Accessed August 11, 2012."},{"key":"10.1016\/j.rdc.2012.08.017_bib84","unstructured":"Ustekinumab for the Treatment of Patients With Active Ankylosing Spondylitis (TOPAS). Available at: ClinicalTrials.gov [Identifier: NCT01330901]. Accessed August 11, 2012."},{"key":"10.1016\/j.rdc.2012.08.017_bib85","first-page":"2486D","article-title":"Interleukin-17A blockade with secukinumab reduces spinal inflammation in patients with ankylosing spondylitis as early as week 6, as detected by magnetic resonance imaging","volume":"63","author":"Baraliakos","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.017_bib86","unstructured":"Study of apremilast to treat subjects with active ankylosing spondylitis (POSTURE). Available at: ClinicalTrials.gov [Identifier: NCT01583374]. Accessed August 11, 2012."},{"key":"10.1016\/j.rdc.2012.08.017_bib87","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0140-6736(08)60593-0","article-title":"Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"Suppl 3","key":"10.1016\/j.rdc.2012.08.017_bib88","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/annrheumdis-2012-eular.1849","article-title":"Tocilizumab (TCZ) is not effective for the treatment of ankylosing spondylitis (AS): results of a phase 2, international, multicentre, randomised, double-blind, placebo-controlled trial","volume":"71","author":"Sieper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.017_bib89","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/art.27383","article-title":"Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial","volume":"62","author":"Song","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.017_bib90","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jbspin.2011.02.018","article-title":"Lack of efficacy of abatacept in axial spondyloarthropathies refractory to tumor-necrosis-factor inhibition","volume":"79","author":"Lekpa","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.rdc.2012.08.017_bib91","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1136\/ard.2010.145946","article-title":"Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.017_bib92","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00403-011-1172-6","article-title":"Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic","volume":"304","author":"Velez","year":"2012","journal-title":"Arch Dermatol Res"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X12000762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X12000762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:11:33Z","timestamp":1760181093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X12000762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":92,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0889857X12000762"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2012.08.017","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy for Spondyloarthritis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2012.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}